Nationwide Fund Advisors boosted its position in Amedisys Inc. (NASDAQ:AMED) by 577.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,964 shares of the company’s stock after buying an additional 105,671 shares during the period. Nationwide Fund Advisors owned approximately 0.37% of Amedisys worth $6,258,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMED. Norges Bank acquired a new position in Amedisys during the fourth quarter valued at about $13,561,000. Renaissance Technologies LLC raised its position in Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock valued at $30,498,000 after buying an additional 282,600 shares in the last quarter. Emerald Acquisition Ltd. acquired a new position in Amedisys during the second quarter valued at about $10,888,000. Adage Capital Partners GP L.L.C. acquired a new position in Amedisys during the first quarter valued at about $4,834,000. Finally, Panagora Asset Management Inc. raised its position in Amedisys by 155.4% in the first quarter. Panagora Asset Management Inc. now owns 164,272 shares of the company’s stock valued at $7,941,000 after buying an additional 99,952 shares in the last quarter. 91.45% of the stock is currently owned by institutional investors and hedge funds.
Amedisys Inc. (NASDAQ:AMED) traded down 0.73% during midday trading on Tuesday, hitting $47.60. The company’s stock had a trading volume of 147,805 shares. The company’s 50 day moving average price is $48.43 and its 200 day moving average price is $49.61. The firm has a market cap of $1.60 billion, a P/E ratio of 41.64 and a beta of 1.05. Amedisys Inc. has a 12 month low of $31.16 and a 12 month high of $55.16.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported $0.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.42. Amedisys had a net margin of 2.78% and a return on equity of 12.17%. The company earned $360 million during the quarter, compared to analyst estimates of $353.07 million. During the same period in the previous year, the business earned $0.43 EPS. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. Analysts expect that Amedisys Inc. will post $1.69 EPS for the current year.
Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Amedisys from a “hold” rating to a “sell” rating in a report on Monday, July 11th. Jefferies Group reaffirmed a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and reduced their target price for the company from $57.00 to $55.00 in a report on Wednesday, August 3rd. Finally, Stephens started coverage on Amedisys in a report on Thursday, June 16th. They set an “equal weight” rating and a $55.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $51.75.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc. (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.